Abstract:Background: This study aimed to investigate the influence of CYP2D6 polymorphisms on risperidone plasma concentrations in patients with schizophrenia. Based on pharmacogenomics, we examined whether plasma concentration of risperidone is associated with clinical response and adverse side-effects. Methods: We recruited patients with chronic schizophrenia who were then treated with risperidone. The CYP2D6 genotypes were determined using targeted sequencing. All high-frequency mutation sites of the nine exons of the gene were assayed in the present study. Plasma concentrations of risperidone and 9-hydroxyrisperidone (9-OH-RIS) were measured using high-performance liquid chromatography (HPLC). Psychiatric symptoms were monitored using The Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI). Adverse effects were evaluated using the Barnes Akathisia Scale (BAS) and Extrapyramidal Symptom Rating Scale (ESRS). Follow-up visits were scheduled at weeks 2,4, and 8 after treatment initiation. Results: Among the 76 patients, 100 C > T (rs1065852), 1038 C > T (rs1081003), 1662 G > C (rs1058164), 2851 C > T (rs16947), and 4181G > C (rs1135840) variants were detected. The most common allele was CYP2D6*10 (81.6%), whereas CYP2D6*2 (9.2%) and CYP2D6*5 (17.1%) were relatively rare. Plasma levels of risperidone and the risperidone/9-OH risperidone ratio (R/9-OH) were significantly increased in individuals with CYP2D6*10 (P < 0.05). The change in PANSS score, weight, high-density lipoprotein (HDL) level, prolactin (PRL) level, and ESRS were significantly different from baseline, between the different genotypes (P < 0.01). Moreover, individuals with CYP2D6*10 homozygous (TT) mutations were associated with higher risperidone concentration and R/9-OH ratio than those with heterozygous mutations (CT) (P < 0.01). A change from baseline in BPRS scores was observed only during week 8 and was different between heterozygous and homozygous mutations. As for the C2851T polymorphism, the incidence of adverse metabolic effects was significantly different between the C/C and C/T genotypes (P < 0.01). Regarding the G4181C polymorphisms, the changes from baseline in GLU and TG, were different between the C/C and C/G genotypes (P < 0.01). Conclusions: The genotype of CYP2D6 significantly influences the plasma concentration of risperidone and may subsequently influence the adverse side-effects following risperidone treatment, while also exerting a slight influence on clinical outcomes.

Influences of CYP2D6 * 10 Polymorphisms on the Pharmacokinetics of Iloperidone and Its Metabolites in Chinese Patients with Schizophrenia: a Population Pharmacokinetic Analysis

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone

Influence of Cyp2d6*10b Genotype on Pharmacokinetics of Propafenone Enantiomers in Chinese Subjects

Effect of Cyp2d6*10 Genotype on Propafenone Pharmacodynamics in Chinese Patients with Ventricular Arrhythmia

Influence of CYP2D6 Gene Polymorphisms on the Pharmacokinetics of Aripiprazole in Healthy Chinese Subjects.

Influence of CYP2D6 Genetic Polymorphism on Pharmacokinetics of Paroxetine in Chinese Healthy People

The impact of CYP3A5*3 on oral quetiapine: A population pharmacokinetic model in Chinese bipolar disorder patients

Effects of 22 CYP2D6 Genetic Variations Newly Identified in Chinese Population on Olanzapine Metabolism in Vitro.

Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis

Effects of CYP2D6 Gene Polymorphism on Plasma Concentration and Therapeutic Effect of Olanzapine

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.

Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety.

Pharmacokinetics of the New Proton Pump Inhibitor Ilaprazole in Chinese Healthy Subjects in Relation to CYP3A5 and CYP2C19 Genotypes.

Relationship between cytochrome P450 CYP2D6*10B gene and therapeutic effect of risperidone

Effect of Cyp2d6 Genetic Polymorphism on the Metabolism of Citalopram in Vitro

Cyp2d6 Phenotype Determines Pharmacokinetic Variability of Propafenone Enantiomers in 16 Han Chinese Subjects

CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations.

Effect of genetic polymorphism of CYP2B6 * 6 on pharmacokinetics and pharmacodynamics of single dose propofol in Chinese healthy subjects

Impact of CYP2C9 polymorphism found in the Chinese population on the metabolism of propofol in vitro.

Ndt_a_355985 731..736